Concept
Clinical research
Related people (43)
Stewart Cole
Professor Stewart Cole is an international authority in bacterial molecular-genetics and genomics. He has made outstanding contributions in several fields including: bacterial anaerobic electron transport; genome analysis of retroviruses and papillomaviruses; antibiotic resistance mechanisms; and the molecular microbiology of toxigenic clostridia. His studies on isoniazid and multidrug resistance in Mycobacterium tuberculosis, together with his pioneering work on the pathogenicity, evolution and genomics of the tubercle and leprosy bacilli, have made him an undisputed leader in the field of mycobacterial research. The findings of his research are of direct relevance to public health and disease-control in both the developing world and the industrialised nations. He has published over 250 scientific papers and review articles, and holds many patents.
Patrick Aebischer
Patrick Aebischer a achevé une formation en Médecine (1980) et en Neurosciences (1983) aux Universités de Genève et de Fribourg en Suisse.
De 1984 à 1992, Patrick Aebischer a travaillé à Brown University (USA) au sein du Département des Neurosciences et au Département des Biomatériaux et des Organes Artificiels en tant que Professeur assistant, puis Professeur associé.
En 1992, Patrick Aebischer a été nommé Professeur de la Division Autonome de Recherche Chirurgicale et du Centre de Thérapie Génique (DARC) au Centre Hospitalier Universitaire Vaudois (CHUV) à Lausanne.
En 1999, Le Conseil Fédéral a nommé Patrick Aebischer en tant que Président de l'Ecole Polytechnique Fédérale de Lausanne (EPFL). Il a pris ses fonctions à la Présidence de lEPFL en mars 2000, position qu'il a occupée jusqu'au 31 décembre 2016.
Patrick Aebischer est membre de maintes sociétés professionnelles, tant en Europe quaux Etats-Unis.
Patrick Aebischer a fondé trois start-up de biotechnologies. Il siège au conseil d'administration de Lonza, de Logitech et de Nestlé. Il préside également l'advisory board du Novartis Venture Fund. Patrick Aebischer est membre du conseil de fondation du Festival de Jazz de Montreux, du Festival de Verbier et de la Fondation Jacobs.
Les recherches quil poursuit actuellement dans son laboratoire se concentrent sur le développement d'approches de thérapie cellulaire et de transfert génique pour le traitement des maladies neurodégénératives.
Claudio Bruschini
Claudio Bruschini holds an MSc in high energy physics from the University of Genova and a PhD in Applied Sciences from the Vrije Universiteit Brussel (VUB). He started his career with INFN (Italy, 1993), in the WA92 CERN collaboration (particle physics), and then moved to CERN as a Fellow in the European GP-MIMD2 project, attached to the NA48 collaboration (particle physics, parallel programming, 1994-1995). He then started his close collaboration with EPFL, first in the DeTeC (Demining Technology Center) project (sensors for landmine detection/humanitarian demining, 1996-1997). After DeTeC's end, he started the first of a series of fruitful collaborations with the Vrije Universiteit Brussel (VUB) on humanitarian demining related R&D (1998). This was followed by the EUDEM survey project (The European Union in Humanitarian Demining, 1998), the EUDEM2 three year EC sponsored support measure (www.eudem.info, 2001-2004), and the DELVE support action (www.delve.vub.ac.be, 2007). In parallel he started working within the EPFL's AQUA group (Advanced Quantum Architectures, Edoardo Charbon), on topics as diverse as ultrasonic sensors for in-air application, optical 3D and high speed 2D sensing, sensor networks, or tracking/motion capture systems, in particular for the preparation of research projects. This culminated in the European MEGAFRAME (www.megaframe.eu, FP6, 2006-2010, SPAD arrays and related in-pixel time stamping electronics in deep submicron CMOS technology) and SPADnet (www.spadnet.eu, FP7, 2010-2014, networked SPAD arrays for Positron Emission Tomography) projects, coordinated by EPFL-AQUA. As from 2009 he also worked with Dario Floreano on the management of the CURVACE Curved Artificial Compound Eyes FP7 project (www.curvace.org), coordinated by EPFL-LIS. He was also active with CHUV (Lausanne University Hospital) within EndoTOFPET-US (endoscopic PET) as well as on a CTI project devoted to the development of a new hand-held standalone tool for tracer-guided medical procedures. In 2014 he had also the pleasure of joining the EPFL ICLAB of Christian Enz during its ramp-up phase, collaborating on device related topics (SNF GigaRadMOST) and biomedical R&D (NanoTera WiseSkin). Claudio is now fully with EPFL’s Advanced Quantum Architecture (AQUA). He has also been active as independent scientific consultant, under the label CBR Scientific Consulting, on the preparation of (European) R&D project proposals and the execution of individual studies, and worked in 2006 for a local start-up as operations manager and R&D advisor.... but this is another story. An unauthorized early biography is available at http://lami.epfl.ch/team/claudiob/...
Marcello Ienca
Dr. Marcello Ienca is a Principal Investigator at the College of Humanities at EPFL where he leads the ERA-NET funded Intelligent Systems Ethics research unit. He is also an affiliate member of the Health Ethics and Policy unit, Department of Health Sciences and Technology, and an ordinary member of the
Competence for Rehabilitation Engineering & Science
at ETH Zurich, Switzerland.
Dr. Ienca's scholarship focuses on the ethical, legal, social and policy implications of emerging technologies. In particular, he investigates the broader implications of new (and often converging) sociotechnical trends such as Artificial Intelligence (AI), big data, digital epidemiology, robotics, assisted living, digital health, social media, dual use, and neurotechnology. He and his team use both theoretical and empirical methods to explore the requirements for responsible innovation, ethically-aligned technology design, user-centred design, and human-centered technology assessment.
Dr. Ienca is actively involved in science and technology policy within international organizations and professional societies. In particular, he is an appointed member of the Organisation for Economic Co-operation and Development’s (OECD) Steering Committee on Neurotechnology and the representative of the Swiss Delegation (appointed by the Swiss State Secretariat for Education, Research and Innovation, SERI). He has also been invited to serve as an expert advisor to the Council of Europe’s Ad Hoc Committee on Artificial Intelligence and the Bioethics Committee. Dr. Ienca has written reports for the OECD, the Council of Europe, and the European Parliament's Panel for the Future of Science and Technology. He is a Member of the Board of Directors of the Italian Neuroethics Society (SINe), a former Board Member and current member of the Nominating Committee of the International Neuroethics Society (INS). Ienca is a member of the Editorial Board of several academic journals such as Neuroethics, Bioethica Forum, Frontiers in Neuroergonomics and Frontiers in Genetics.
Ienca has received several awards for social responsibility in science and technology such as the Vontobel Award for Ageing Research (Switzerland), the Prize Pato de Carvalho (Portugal), the Sonia Lupien Award (Canada), the Paul Schotsmans Prize from the European Association of Centres of Medical Ethics (EACME) and the Data Privacy Plaque of Honour, awarded by the Italian Data Protection Authority. He has authored one monograph, several edited volumes, 60 scientific articles in peer-review journals, several book chapters and is a frequent contributor to Scientific American. His research was featured in academic journals such as
Neuron
,
Nature Biotechnology
,
Nature Machine Intelligence
,
Nature Medicine
and media outlets such as
Nature
,
The New Yorker
,
The Guardian
,
The Times
,
Die Welt
,
The Independent
, the
Financial Times
and others.
Furthermore, Dr. Ienca strongly supports open science, outreach and public engagement. He is committed to a holistic view of research that is not restricted to academia alone but involves an open approach to science communication, outreach and public engagement. Among other things, he is an open-science and open-data enthusiast and a human rights activist. He believes that there can be no ethical technological innovation without global justice.